HEC Pharm
HEC Pharm (广东东阳光药业股份有限公司) is a vertically integrated Chinese pharmaceutical company founded in 2003, focused on anti-infectives, chronic disease, and oncology therapeutics. Listed on HKEX as 06887.HK in August 2025, the company develops, manufactures, and commercializes innovative drugs, generics, and biosimilars across China, Europe, and North America.
- Company typePublic
- Founded2003
- HeadquartersDongguang, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What HEC Pharm does
HEC Pharm (广东东阳光药业股份有限公司 / Sunshine Lake Pharma Co., Ltd.) is a vertically integrated Chinese pharmaceutical company founded in 2003 and headquartered in Dongguan, China. It operates across drug discovery, manufacturing, and commercialization for innovative drugs, modified new drugs, generics, and biosimilars, with strategic focus on anti-infectives, chronic diseases, and oncology therapeutic areas. Following its August 2025 listing on the Hong Kong Stock Exchange (06887.HK) via merger-absorption of Yichang HEC Changjiang Pharmaceutical, the company employs 6,000+ staff including 1,100+ R&D personnel, holds 2,500+ invention patent applications and 1,300+ granted patents, and has 68 products approved in Europe and the US. Its commercial portfolio includes Kewei® oseltamivir (the leading oseltamivir brand in China and first pediatric formulation globally), Dongweien® emitasvir and the Encofosbuvir/Netanasvir HCV combination, the Yibigan® insulin glargine franchise (BLA under US FDA review), and creflotinib for AML.
The company's clinical pipeline includes HCN30227 (siRNA for chronic hepatitis B using the proprietary HEC-GalNova liver-targeting delivery system), HEC169584 (a THR-β agonist for NASH discovered via the HEC-GEN model), Ifenidone (Phase II data for IPF), and creflotinib (FLT3 inhibitor, Phase III). It operates the State Key Laboratory of Anti-Infective Drug Development (national-level research platform) and three core R&D platforms covering chemical drug discovery, biologics, and innovative formulation technologies.
HEC Pharm has built a proprietary AI infrastructure spanning molecular generation (HEC-GEN), retrosynthesis planning (HEC-SynAI), formulation design (HEC-PharmAI), pharmacokinetics prediction (HEC-PK), and literature/patent intelligence (HEC-Finder), consolidated under an integrated AIDD platform and an AI4S Joint Laboratory with DeepTech. Revenue derives from pharmaceutical product sales via a direct global sales network covering China domestic, Europe, and North America, supplemented by out-licensing of innovative pipeline assets such as HEC88473 to Apollo (UK) and creflotinib commercialization rights to 3SBio.
HEC Pharm firmographics
Firmographics- Name
- HEC Pharm
- Legal name
- 广东东阳光药业股份有限公司
- Website
- https://hecpharm.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Ipo
- Headcount range
- 1,001–5,000 employees
- Short description
- HEC Pharm (广东东阳光药业股份有限公司) is a vertically integrated Chinese pharmaceutical company founded in 2003, focused on anti-infectives, chronic disease, and oncology therapeutics. Listed on HKEX as 06887.HK in August 2025, the company develops, manufactures, and commercializes innovative drugs, generics, and biosimilars across China, Europe, and North America.
- Ownership category
- akta.pro rank
HEC Pharm industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Oncology Specialty Pharmaceuticals (HLAIACAA), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where HEC Pharm is headquartered
LocationHeadquarters
- HQ city
- Dongguang
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
HEC Pharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Revenue from sales of innovative drugs, modified new drugs, generic drugs, and biosimilars across therapeutic areas including anti-infectives, chronic diseases, and oncology. Products sold globally through own sales network.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
HEC Pharm product offering
Product offeringCore offering
HEC Pharm is a vertically integrated pharmaceutical company engaged in the R&D, manufacturing, and commercialization of innovative drugs, modified new drugs, generic drugs, and biosimilars. The company strategically focuses on anti-infective, chronic disease, and oncology therapeutic areas, leveraging AI-driven drug discovery platforms across the full R&D-to-CMC pipeline. It operates a global sales network covering China, Europe, and North America.
Product overview
HEC Pharm operates as a vertically integrated pharmaceutical company combining independent R&D platforms, international-standard manufacturing, and a global sales network. The portfolio consists of six AI-powered drug discovery platform modules (HEC-SynAI for retrosynthetic planning, HEC-Finder for literature/patent intelligence, HEC-PharmAI for formulation, HEC-PK for pharmacokinetics prediction, HEC-GEN for molecular generation, and the integrated HEC Drug Intelligent Discovery Platform), five commercialized pharmaceutical products (Kewei® oseltamivir phosphate granules and capsules for influenza, Dongweien® emitasvir phosphate capsules for HCV, Yibigan® insulin glargine injection for diabetes, and the 2025-approved艾考磷布韦/磷酸萘坦司韦 HCV combination), and multiple clinical-stage candidates (HECN30227 siRNA for hepatitis B, HEC169584 THR-β agonist for NASH, creflotinib for AML, and ifeonidone for IPF). The company strategically focuses on anti-infective, chronic disease, and oncology therapeutic areas, leveraging AI to accelerate the full drug discovery-to-CMC pipeline.
Differentiator
Problem solved
Functional benefit
Brands
- 可威® (Kewei®): 磷酸奥司他韦颗粒 (Oseltamivir Phosphate Granules) and 磷酸奥司他韦胶囊 (Oseltamivir Phosphate Capsules) — leading oseltamivir brand for influenza treatment and prevention, first pediatric-appropriate oseltamivir formulation globally. Awarded China Patent Gold Award in 2025.
- 东卫恩® (Dongweien®)
- 东卫卓® (Dongweizhuo®)
- 东英贺® (Dongyinghe®)
- 宜必甘® (Yibigan®)
- HEC-SynAI
- HEC-Finder
- HEC-PK (HEC-PK Model 1.0)
- HEC-PharmAI
- HEC-GEN
- HEC-GalNova (N-乙酰半乳糖胺)
- 宜必锐® (Yibirui®)
- 宜必霖®R (Yibilin®R)
Products and services
- Kewei® Oseltamivir Phosphate Granules (可威® 磷酸奥司他韦颗粒) Oseltamivir phosphate granules for treatment and prevention of influenza A and B in adults and children aged 1 year and above. First pediatric-specific anti-influenza formulation globally, with leading market share in China.
- Kewei® Oseltamivir Phosphate Capsules (可威® 磷酸奥司他韦胶囊) Oseltamivir phosphate capsules for treatment of influenza A and B in adults and children aged 1 year and above (within 48 hours of symptom onset) and prevention in adults and adolescents aged 13 years and above.
- Dongweien® Emitasvir Phosphate Capsules (东卫恩® 磷酸依米他韦胶囊) NS5A inhibitor used in combination with sofosbuvir for treatment of genotype 1 non-cirrhotic chronic hepatitis C in adults. Overall SVR12 rate of 99.8%. China's only hepatitis C treatment drug with proprietary independent IP.
- Yibigan® Insulin Glargine Injection (宜必甘® 甘精胰岛素注射液)
Quantifiable outcome
- HECN30227 siRNA drug: achieved 96% FVC decline delay vs 47% for pirfenidone in IPF Phase II trial
- +4 more outcomes
Companies that use HEC Pharm
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
HEC Pharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature6 records
HEC Pharm partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- 3SBio (三生制药 / 沈阳三生制药有限责任公司)coreHEC Pharm granted 3SBio exclusive commercialization rights for Creflotinib (benzenesulfonic acid crenoltinib) in mainland China. HEC Pharm receives RMB 60 million upfront payment plus potential regulatory and commercial milestone payments. HEC Pharm continues to be responsible for R&D, registration (as MAH), and manufacturing while 3SBio handles exclusive commercialization. Agreement effective for at least 15 years from first commercial sale.
- DeepTech (深势科技)coreHEC Pharm and DeepTech established an AI4S Joint Laboratory focused on high-value R&D scenarios in biomedicine. DeepTech provides its science AI platform including Hermite drug design platform, RiDYMO difficult-to-drug target R&D platform, and scientific model system DeepPot · YuZhi. HEC Pharm integrates these AI tools into its AIDD platform to accelerate target discovery and preclinical candidate screening. Full strategic cooperation agreement signed at 2024 Science Intelligence Forum.
- Apollo (UK)coreHEC Pharm licensed HEC88473 (innovative drug) for exclusive development and commercialization rights outside Greater China to UK-based Apollo company. Deal value close to USD 1 billion. Represents major out-licensing BD deal for HEC Pharm's innovative pipeline.
- Baidu Health (百度健康)minorHEC Pharm partnered with Baidu Health on digital marketing including keyword search optimization, content optimization, and professional Q&A for influenza and related disease education. Collaborated on 'Influenza High-Incidence Season Prevention Should Come First' public welfare campaign with CCTV and Baidu Health.
Scale indicators18 records
Recent moves7 records
Expansion highlights6 records
HEC Pharm competitors and assessment
Company assessmentDirect peers
- BeiGene: Chinese-headquartered oncology-focused innovative pharma with HKEX and Nasdaq listings, global commercial footprint, and partnerships with multinational pharma (Amgen, Novartis). Comparable go-global strategy and HKEX listing to HEC, though more concentrated in oncology.
- Hutchmed (HUTCHMED): Hong Kong and Nasdaq-listed Chinese innovative oncology pharma with global out-licensing partnerships (AstraZeneca, Eli Lilly). Comparable to HEC in its pursuit of innovative drug development, HKEX listing, and strategy of combining Chinese R&D with global commercialization partnerships.
- Innovent Biologics: Chinese innovative biologics company with HKEX listing and a portfolio including oncology and chronic disease biologics with multiple NDA-stage assets. Comparable to HEC's biologic and biosimilar strategy and its evolving pipeline of innovative candidates.
- Hansoh Pharmaceutical: Hong Kong-listed Chinese pharma specializing in innovative drugs across oncology, anti-infectives, and CNS, with a rapidly growing R&D pipeline. Similar mid-cap profile to HEC with comparable HK listing and focus on transitioning from generics to innovative therapeutics.
- Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharmaceutical company with a comparable diversified pipeline spanning oncology, anti-infectives, and chronic diseases. Like HEC, Hengrui is vertically integrated with R&D, manufacturing, and global commercialization (FDA-approved products). Both companies target similar therapeutic areas and pursue out-licensing strategies for global expansion.
- CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma with similar breadth across innovative drugs, generics, and biosimilars, including significant anti-infective and oncology franchises. CSPC's vertical integration from API through commercial sales and its HKEX Main Board listing make it a directly comparable platform business model to HEC.
- Shanghai Fosun Pharmaceutical: Diversified Chinese pharma with vertically integrated operations spanning innovative drugs, generics, biosimilars, and international assets (acquired Gland Pharma). Comparable scale and breadth of therapeutic areas including anti-infectives, and similar HKEX A-share dual listing structure.
- Sino Biopharmaceutical: Major Chinese pharma with a diversified therapeutic portfolio including hepatitis drugs, oncology, and chronic disease products. Through its subsidiary Chia Tai Tianqing, it directly competes in the anti-infective space. Listed on HKEX, providing a directly comparable public-market peer.
- Chia Tai Tianqing (Sino Biopharm subsidiary): Anti-infective and oncology-focused Chinese pharma and direct competitor to HEC's Kewei franchise. Both companies compete in antiviral therapeutics and hepatitis treatments, with similar hospital sales channels and NRDL-driven commercial dynamics.
Others
- WuXi AppTec: Chinese pharmaceutical R&D services platform providing CRO/CDMO capabilities. Not a direct competitor but an adjacent ecosystem participant whose services HEC could potentially use or whose tech stack overlaps with HEC's AI-driven discovery platform investments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
HEC Pharm social profiles
Digital presenceHEC Pharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
HEC Pharm leadership team
Management profileNumber of profiles
Profiles3 records
HEC Pharm subsidiaries and ownership
Company hierarchySubsidiaries4 records
HEC Pharm funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HEC Pharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HEC Pharm
What does HEC Pharm do?
HEC Pharm is a vertically integrated pharmaceutical company engaged in the R&D, manufacturing, and commercialization of innovative drugs, modified new drugs, generic drugs, and biosimilars. The company strategically focuses on anti-infective, chronic disease, and oncology therapeutic areas, leveraging AI-driven drug discovery platforms across the full R&D-to-CMC pipeline. It operates a global sales network covering China, Europe, and North America.
Is HEC Pharm a public or private company?
HEC Pharm is a public company. It is classified as public and is currently ipo.
When was HEC Pharm founded?
HEC Pharm was founded in 2003. It employs 1,001 to 5,000 people.
Where is HEC Pharm based?
HEC Pharm is headquartered in Dongguang, China, in the Asia region.
How does HEC Pharm make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are HEC Pharm's main competitors?
Direct peers on record are BeiGene, Hutchmed (HUTCHMED), Innovent Biologics, Hansoh Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, CSPC Pharmaceutical Group, Shanghai Fosun Pharmaceutical, Sino Biopharmaceutical and Chia Tai Tianqing (Sino Biopharm subsidiary). WuXi AppTec is listed as an others.
Does HEC Pharm have an API?
No public API is recorded for HEC Pharm.
What industry is HEC Pharm in?
HEC Pharm's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.